Yahoo
The SIM0505 employs a unique epitope which enhances tumour binding.
Yahoo
NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rightsPhase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025Initial Phase 1 clinical data is expected in the first half of 2026NextCure also gains rights to Simcere Zaiming’s proprietary linker and payload for use in an ADC directed to a NextCure novel target; Simcere Zaiming will have rights to greater China BELTSVILLE, Md
Yahoo
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients […]
Yahoo
LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimizationThe study is currently enrolling in dose escalationPoster to be presented June 2, 2025, 1:30 pm-4:30 pm CT BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat canc
Yahoo
Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025Plan to provide a proof of concept data readout in the first half of 2026Cash of approximately $55.9 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., May 01, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and
Yahoo
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the we
Current Value
$0.431 Year Return
Current Value
$0.431 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ACET | 34.29% | $50.54M | -44.45% | 0.00% |
| SRPT | 32.35% | $1.74B | -88.51% | 0.00% |
| CHMI | 27.83% | $87.52M | -26.17% | 21.66% |
| DYN | 25.27% | $986.63M | -74.95% | 0.00% |
| TU | 24.00% | $24.83B | +9.19% | 7.12% |
| ENTA | 23.30% | $164.60M | -42.75% | 0.00% |
| SPRY | 21.84% | $1.58B | +85.80% | 0.00% |
| ABCL | 21.41% | $1.04B | +25.99% | 0.00% |
| SYRE | 21.27% | $934.88M | -34.89% | 0.00% |
| IMNM | 21.19% | $736.56M | -27.65% | 0.00% |
| ARR | 21.09% | $1.37B | -13.88% | 17.20% |
| EE | 20.86% | $911.59M | +53.92% | 0.72% |
| ACLX | 20.84% | $3.56B | +21.48% | 0.00% |
| AOMR | 20.78% | $222.31M | -23.28% | 13.51% |
| GENI | 20.70% | $2.42B | +88.79% | 0.00% |
| ORC | 20.51% | $750.98M | -15.49% | 20.47% |
| DX | 20.45% | $1.31B | +4.26% | 14.68% |
| COGT | 20.39% | $822.04M | -12.38% | 0.00% |
| CRON | 20.30% | $740.00M | -15.42% | 0.00% |
| MGTX | 20.28% | $520.77M | +64.47% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CTLP | -19.76% | $806.42M | +66.57% | 0.00% |
| SATS | -18.17% | $8.15B | +56.43% | 0.00% |
| AJG | -14.81% | $81.82B | +21.94% | 0.79% |
| ILPT | -13.59% | $304.92M | +24.93% | 0.86% |
| VRA | -13.30% | $65.08M | -59.55% | 0.00% |
| PULM | -12.66% | $24.14M | +230.50% | 0.00% |
| GALT | -11.88% | $140.51M | -2.63% | 0.00% |
| KMB | -11.71% | $43.67B | -4.62% | 3.76% |
| DCGO | -11.44% | $150.64M | -49.16% | 0.00% |
| OXM | -11.34% | $633.56M | -57.62% | 6.28% |
| WTW | -11.34% | $30.50B | +17.36% | 1.17% |
| ERIE | -11.27% | $16.40B | -3.95% | 1.50% |
| BRBR | -11.13% | $7.46B | -0.25% | 0.00% |
| SAGE | -11.08% | $568.61M | -16.08% | 0.00% |
| BURL | -10.89% | $14.95B | +0.65% | 0.00% |
| RYAN | -10.83% | $8.56B | +17.91% | 0.69% |
| TEVA | -10.78% | $19.08B | +0.54% | 0.00% |
| PG | -10.63% | $377.99B | -1.64% | 2.53% |
| DT | -9.87% | $16.30B | +19.66% | 0.00% |
| SVV | -9.70% | $1.66B | -14.45% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTF | 20.21% | $31.12M | 1.25% |
| EETH | 20.07% | $56.25M | 0.95% |
| GNOM | 19.93% | $44.38M | 0.5% |
| XBI | 19.48% | $4.84B | 0.35% |
| ETH | 19.35% | $1.29B | 0% |
| EZET | 19.31% | $33.83M | 0% |
| QETH | 19.23% | $21.98M | 0.25% |
| ETHV | 19.18% | $114.64M | 0% |
| CETH | 19.13% | $22.01M | 0% |
| ETHW | 19.12% | $257.36M | 0% |
| FETH | 19.10% | $1.18B | 0.25% |
| ETHA | 19.04% | $4.25B | 0.25% |
| JPLD | 18.99% | $1.76B | 0.24% |
| ETHE | 18.73% | $2.72B | 2.5% |
| PTH | 18.34% | $100.70M | 0.6% |
| HYDR | 18.08% | $32.24M | 0.5% |
| SRET | 17.88% | $185.23M | 0.59% |
| SATO | 17.65% | $11.02M | 0.6% |
| ECH | 17.53% | $629.07M | 0.6% |
| MORT | 17.35% | $304.10M | 0.42% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| HIGH | -12.52% | $190.20M | 0.52% |
| USDU | -12.10% | $163.19M | 0.5% |
| CCOR | -10.35% | $51.54M | 1.18% |
| VIXY | -9.80% | $165.58M | 0.85% |
| TAIL | -8.62% | $99.49M | 0.59% |
| BTAL | -8.32% | $295.67M | 1.43% |
| UUP | -8.09% | $209.45M | 0.77% |
| FTSD | -6.54% | $231.68M | 0.25% |
| WEAT | -4.70% | $117.67M | 0.28% |
| IYK | -4.65% | $1.45B | 0.4% |
| MEAR | -4.44% | $1.13B | 0.25% |
| EIS | -4.38% | $311.65M | 0.59% |
| SOYB | -3.90% | $26.59M | 0.22% |
| ISRA | -3.74% | $108.69M | 0.59% |
| JBBB | -3.67% | $1.36B | 0.48% |
| XLP | -3.49% | $15.86B | 0.09% |
| FSTA | -3.13% | $1.35B | 0.084% |
| VDC | -3.05% | $7.59B | 0.09% |
| PHDG | -2.91% | $89.87M | 0.39% |
| JUCY | -2.88% | $269.60M | 0.6% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PDM | -<0.01% | $920.62M | +2.35% | 5.07% |
| BF.B | 0.01% | $13.17B | -34.44% | 3.20% |
| SDHC | 0.01% | $182.53M | -5.54% | 0.00% |
| ADSK | -0.01% | $66.68B | +25.74% | 0.00% |
| FLNC | -0.01% | $959.48M | -53.78% | 0.00% |
| RS | -0.01% | $16.90B | +13.61% | 1.43% |
| UPS | -0.02% | $88.46B | -22.56% | 6.28% |
| LFCR | 0.02% | $294.72M | +68.64% | 0.00% |
| MSA | 0.02% | $6.73B | -7.25% | 1.21% |
| APPS | 0.02% | $623.71M | +247.02% | 0.00% |
| WYNN | 0.03% | $10.66B | +18.10% | 0.98% |
| NOAH | -0.04% | $813.45M | +31.55% | 8.67% |
| VRE | 0.05% | $1.38B | -2.32% | 2.51% |
| DLB | -0.06% | $7.26B | -5.95% | 1.71% |
| ACHC | 0.06% | $2.16B | -64.47% | 0.00% |
| WU | -0.06% | $2.87B | -29.57% | 10.79% |
| NDSN | -0.06% | $12.46B | -3.39% | 1.42% |
| CVI | 0.06% | $2.80B | +6.33% | 1.79% |
| NSC | 0.06% | $59.15B | +21.73% | 2.07% |
| G | 0.07% | $7.86B | +41.42% | 1.44% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CMBS | 0.01% | $448.71M | 0.25% |
| FXY | 0.08% | $820.31M | 0.4% |
| FBY | 0.11% | $176.46M | 1.06% |
| CLOZ | -0.16% | $785.57M | 0.5% |
| IBHE | 0.17% | $553.15M | 0.35% |
| TPMN | 0.23% | $30.70M | 0.65% |
| DBA | -0.25% | $792.17M | 0.93% |
| MNA | 0.31% | $232.03M | 0.77% |
| HEZU | 0.32% | $702.36M | 0.53% |
| CSHI | 0.35% | $532.63M | 0.38% |
| COM | -0.36% | $207.17M | 0.72% |
| IBTG | -0.41% | $1.92B | 0.07% |
| HYD | 0.42% | $3.30B | 0.32% |
| HEDJ | 0.43% | $1.69B | 0.58% |
| SPLV | 0.43% | $7.62B | 0.25% |
| LGLV | 0.59% | $1.09B | 0.12% |
| FTXG | 0.66% | $28.63M | 0.6% |
| FMF | 0.67% | $157.12M | 0.95% |
| LDUR | 0.67% | $929.45M | 0.5% |
| ITA | 0.88% | $8.25B | 0.4% |
